Gerresheimer's High-Stakes Turnaround: A Rejected Bid and a Strategic Pivot
22.04.2026 - 14:03:34 | boerse-global.de
The German pharmaceutical packaging specialist Gerresheimer AG is navigating a complex corporate crisis, choosing an independent path forward after reportedly rejecting a significant takeover approach. According to sources cited by Reuters, U.S. packaging giant Silgan Holdings made an informal offer of 41 euros per share in March, a premium of more than double the stock's trading price at the time. The Düsseldorf-based company has declined to pursue the offer, focusing instead on resolving deep-seated accounting issues and executing a crucial asset sale.
At the heart of the company's troubles are accounting irregularities involving so-called bill-and-hold agreements. An independent law firm confirmed systematic breaches of IFRS rules, where goods were invoiced to customers but delivered later, leading to premature revenue recognition. These violations totaled 35 million euros in revenue and 24 million euros in adjusted EBITDA. The fallout has triggered a professional misconduct investigation by German audit watchdog APAS against auditor KPMG, which gave an unqualified opinion on the 2024 accounts despite the errors. Shareholder association DSW is also examining damage claims against former CEO Dietmar Siemssen and ex-CFO Bernd Metzner, with questions surrounding business valuations of approximately 676 million euros.
To stabilize its financial position, management has secured vital breathing room from its creditors. Holders of 96% of the total volume of 870 million euros in promissory note loans agreed to extend the deadline for the audited 2025 financial statements to September 30, 2026. Key financial covenants related to leverage have been suspended until the end of the third quarter of 2026. This provides a runway to complete ongoing investigations into 2024 and 2025 events without immediate lender intervention.
Should investors sell immediately? Or is it worth buying Gerresheimer?
The centerpiece of Gerresheimer's deleveraging strategy is the sale of its U.S. subsidiary Centor Inc., a maker of packaging systems for prescription drugs. CFO Wolf Lehmann has officially launched the process, which is being advised by investment bank Morgan Stanley. The company has already attracted a double-digit number of interested parties and aims to conclude the transaction this year. Centor was carried on the books at a value of 292 million euros at the end of 2024.
Despite the severe challenges, there are signs of operational continuity and investor interest. On April 20, Gerresheimer announced a technology partnership with U.S.-based Milliken & Company to integrate LeneX UltraGuard® technology into primary pharmaceutical packaging, aiming to improve barrier properties for moisture-sensitive drugs. Furthermore, institutional investors like the CastleKnight Master Fund and Deka Investment have recently taken new positions, betting on a potential recovery.
The stock, which has lost roughly 57% over the past twelve months, reflects the precarious situation. It currently trades around 22.24 euros, far below its 52-week high of 64.40 euros. While the shares dipped briefly on the news of the rejected bid, they have shown recent volatility, gaining nearly 23% over a seven-day period as the market acknowledges incremental progress.
The coming months are critical. Gerresheimer aims to publish its audited 2025 annual and consolidated financial statements in June 2026, followed by the half-year report on July 14, 2026. The annual general meeting, originally scheduled for April 16, will be rescheduled after the financial statements are released. The company's ability to finalize the Centor sale on schedule and conclude its internal investigations without further surprises will likely determine the success of its solo turnaround effort.
Ad
Gerresheimer Stock: New Analysis - 22 April
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Gerresheimers Aktien ein!
Für. Immer. Kostenlos.
